Abstract
Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77% without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47%, poor overall quality of life in 40%, and significant problems with physical symptoms in less than 27% of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 1565-1572 |
| Number of pages | 8 |
| Journal | Journal of Clinical Oncology |
| Volume | 14 |
| Issue number | 5 |
| State | Published - May 1 1996 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Intensive outpatient adjuvant therapy for breast cancer : Results of dose escalation and quality of life. / Swain, S. M.; Rowland, J.; Weinfurt, K.; Berg, C.; Lippman, Marc E; Walton, L.; Egan, E.; King, D.; Spertus, I.; Honig, S. F.
In: Journal of Clinical Oncology, Vol. 14, No. 5, 01.05.1996, p. 1565-1572.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intensive outpatient adjuvant therapy for breast cancer
T2 - Results of dose escalation and quality of life
AU - Swain, S. M.
AU - Rowland, J.
AU - Weinfurt, K.
AU - Berg, C.
AU - Lippman, Marc E
AU - Walton, L.
AU - Egan, E.
AU - King, D.
AU - Spertus, I.
AU - Honig, S. F.
PY - 1996/5/1
Y1 - 1996/5/1
N2 - Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77% without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47%, poor overall quality of life in 40%, and significant problems with physical symptoms in less than 27% of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.
AB - Purpose: A dose-escalation study was conducted to determine the maximum- tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cyclophosphamide (CY) in combination with granulocyte colony-stimulating factor (G-CSF) and doxorubicin (DOX) given every 2 weeks for eight cycles as outpatient adjuvant therapy for node-positive breast cancer. A pilot study to assess quality of life (QOL) was performed. Patients and Methods: From March 1991 to April 1993, 19 patients were entered. Patients received escalating doses of CY intravenously (IV) {1,000 mg/m2, 1,500 mg/m2, 2,000 mg/m2, or 2,500 mg/m2) with DOX 40 mg/m2, G-CSF 10 μg/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles. QOL was measured by the Profile of Mood States (POMS), the Psychosocial Adjustment to Illness Scale-Self Report (PAIS-SR), and a 27-item QOL scale. Results: The CY dose of 2,500 mg/m2 every 2 weeks elicited toxicities that required dose reductions secondary to a combination of thrombocytopenia, hematuria, and anemia that required transfusion. The dose of 2,000 mg/m2 resulted in an acceptable toxicity profile. Ninety-two percent of cycles at the 2,000-mg/m2 dose were delivered on schedule and 77% without hospitalization. QOL assessments indicated high levels of distress measured by POMS in 47%, poor overall quality of life in 40%, and significant problems with physical symptoms in less than 27% of all patients for any given cycle. Conclusion: A dose of CY at 2,000 mg/m2 can be administered every 2 weeks with DOX and G-CSF for eight cycles in the outpatient setting with manageable toxicity. The majority of women described levels of physical symptoms and emotional distress as tolerable during treatment.
UR - http://www.scopus.com/inward/record.url?scp=9244239744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9244239744&partnerID=8YFLogxK
M3 - Article
C2 - 8622073
AN - SCOPUS:9244239744
VL - 14
SP - 1565
EP - 1572
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 5
ER -